Using a virus to treat progressive pediatric brain tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the safety and tolerability of a novel oncolytic virus, Ad-TD-nsIL12, administered through intratumoral injection in children with progressive Diffuse Intrinsic Pontine Glioma (DIPG). It employs a single-arm, single-center design with a 3+3 dose escalation approach to assess potential adverse effects and toxicity. The study aims to confirm the safety profile of this innovative treatment following standard therapies like surgery and chemotherapy. Participants will undergo MRI scans to confirm tumor progression before treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Informed consent of the parents or patient.
2. After surgical resection, biopsy, chemotherapy, or radiation therapy, tumor progression must be confirmed by MRI scan.
3. Biopsy is performed prior to injection of Ad-TD-nsIL12 to confirm DIPG (frozen section-based).
4. Pre-enrollment patients LPS (patients aged ≥1 and \<16 years) and KPS (patients aged ≥16 years) ≥ 50.
5. Patient must be, in the investigator opinion, able to comply with all the protocol procedures.
6. Age 1-18 years.
7. A negative pregnancy test in fertile women (women are considered of childbearing potential (WOCBP) after menarche, unless permanently infertile, including hysterectomy, bilateral salpingectomy, and bilateral oophorectomy).
8. Lesion considered by the investigator to be accessible for stereotactic biopsy.

Exclusion Criteria:

1. Serious infections or intercurrent conditions, including but not limited to severe renal failure, liver failure, heart failure, or bone marrow failure, which are not permitted for inclusion according to the investigator's criteria. Patients must be afebrile (\<38℃) at the time of viral therapy.
2. Other investigational medications within 30 days prior to viral treatment.
3. Participants with immunodeficiency, autoimmune disease, or active hepatitis.
4. Any medical or psychological condition that might interfere with the patient's ability to participate if older than 16 years or parents ability when younger than 16, or give informed consent or would compromise the patient's ability to tolerate therapy or any disease that will obscure toxicity or dangerously alter drug metabolism.
5. Tumor with multiple location.
6. Pregnant or breast-feeding females.
7. Severe bone marrow hypoplasia.
8. Transaminases (aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)) or total bilirubin \> 3 times the upper limit of normal.
9. Neutrophils \< 1x10\^9/L.
10. Platelets ≤ 100x10\^9/L.
11. Hemoglobin \< 9g/dl.
12. Patients with Li-Fraumini syndrome or a known germline defect in the retinoblastoma gene or its associated pathways.
13. Administer any type of vaccine within 30 days prior to Ad-TD-nsIL12 administration.
14. Blood transfusions or drugs (such as G-CSF) within 28 days before viral treatment to treat pancytopenia or other hematological disorders.

Where it's running

• Sanbo Brain Hospital, Capital Medical University
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: Hongwei Zhang, Prof. — Capital Medical University
• Study coordinator: Xiao Qian, Dr.
• Email: ryan521q@sina.com
• Phone: 18020295435

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using a virus to treat pediatric brain tumors

  This study is testing a new virus treatment for children with a tough brain tumor called DIPG to see if it is safe and how much of it can be given.

  Recruiting Phase 1 Capital Medical University · Beijing, Beijing Municipality · NCT05717712

• BCB-276 CAR T therapy for DIPG in children and young adults

  This study tests BCB-276, a patient's own CAR T cells against DIPG, after standard radiation, to see if it is safe and can help extend survival.

  Recruiting at 3 sites Phase 2 BrainChild Bio, Inc · Los Angeles, California and 5 other locations · NCT07680439

• VRT106 plus radiotherapy in adults with DMG/DIPG

  This trial tests whether adding VRT106 to radiotherapy is safe and could help adults with DMG/DIPG.

  Recruiting Phase 2 Guangzhou Virotech Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT07589257

• H101 Plus TACE for advanced head and neck cancer

  This study tests whether adding H101 to transarterial chemoembolization can help treat recurrent or metastatic head and neck squamous cell carcinoma.

  Recruiting Phase 2 West China Hospital · Chengdu, Sichuan · NCT07398664

• Comparing tranexamic acid dosing during heart surgery with cardiopulmonary bypass

  This research will test whether three different tranexamic acid dosing schedules keep fibrinolysis suppressed longer and limit bleeding in adults having elective heart surgery with cardiopulmonary bypass.

  Recruiting University of Ioannina · Ioannina · NCT07164300

• Combining Atovaquone with Radiation for Treating Children's Brain Tumors

  This study is testing if adding atovaquone to radiation therapy can help children with aggressive brain tumors feel better and improve their treatment outcomes.

  Recruiting at 2 sites Phase 1 Emory University · Atlanta, Georgia and 1 other locations · NCT06624371

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.